Evidence map›Paper›PMID 30653440›Full record

ReviewCirculation research2019

Statin Toxicity.

Natalie C Ward, Gerald F Watts, Robert H Eckel

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Circulation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06551298 (Multi Center Clinical Study on the Lipid-lowering Efficacy and Safety of Menggongzi Tibetan Tea Special Drink), which is not on this map. Cited by 314 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
314citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06551298 nanot yet recruitingstarted 2024, after this paper: background citation

Multi Center Clinical Study on the Lipid-lowering Efficacy and Safety of Menggongzi Tibetan Tea Special Drink

Ran2024Enrolled129Registered outcomes2Posted comparisons0ConditionsHyperlipidemiasArmsAtorvastatin Calcium 20Mg Tab, Low fat diet, Menggongzi Tibetan Tea Special Drink
PMID 30375494PMID 36858834PMID 31504418PMID 38865662PMID 38399268PMID 35945174PMID 35525255PMID 34778156PMID 34472586PMID 32818824PMID 8531308PMID 30700139other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

314 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Effects of flavonoids on atherosclerosis in ApoEFrontiers in pharmacology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Squalene Epoxidase: Its Regulations and Links with Cancers.International journal of molecular sciences · 2024
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

254 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Natalie C WardFrom the School of Public Health, Curtin University, Perth, Western Australia, Australia (N.C.W.).
Gerald F WattsSchool of Medicine, University of Western Australia, Perth, Australia (N.C.W., G.F.W.).
Robert H EckelDivision of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.H.E.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is now overwhelming evidence to support lowering LDL-c (low-density lipoprotein cholesterol) to reduce cardiovascular morbidity and mortality. Statins are a class of drugs frequently prescribed to lower cholesterol. However, in spite of their wide-spread use, discontinuation and nonadherence remains a major gap in both the primary and secondary prevention of atherosclerotic cardiovascular disease. The major reason for statin discontinuation is because of the development of statin-associated muscle symptoms, but a range of other statin-induced side effects also exist. Although the mechanisms behind these side effects have not been fully elucidated, there is an urgent need to identify those at increased risk of developing side effects as well as provide alternative treatment strategies. In this article, we review the mechanisms and clinical importance of statin toxicity and focus on the evaluation and management of statin-associated muscle symptoms.

Indexed as

AnimalsBiomarkersCardiovascular DiseasesCholesterol, LDLDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMuscle, SkeletalMuscular DiseasesRisk AssessmentRisk FactorsBiomarkersCholesterol, LDLHydroxymethylglutaryl-CoA Reductase Inhibitorsatherosclerosischolesterolhyperlipidemiariskstatin

Identifiers

PMID30653440

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.